Oragenics, Inc. Resumes Phase 2 Clinical Trial of AG013 in Oral Mucositis Following Positive Routine Safety Review (Business Wire)
UF Innovate | Sid Martin alumni startup Oragenics, Inc., a leader in the development of new antibiotics against infectious diseases and effective... Read More
Oragenics Touts New Drug to Fight Clostridium Difficile (Proactive Investors)
New research by Sid Martin Biotech alum Oragenics Inc., now a Tampa-based clinical-stage biotech group, has uncovered a novel type of antibiotic... Read More